Mainz Biomed NV (MYNZ) FinancialsMYNZFinancialMainz Biomed NV

Evaluating the bottom line, Mainz Biomed NV maintains a gross margin of 66.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2822.07%, while the net margin is -2910.26%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MYNZ converts its operational activities into shareholder value.

In the context of the broader market, MYNZ competes directly with industry leaders such as GRDX and TCRT. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, MYNZ's gross margin of 66.12% stands against GRDX's -42.52% and TCRT's N/A. Such benchmarking helps identify whether Mainz Biomed NV is trading at a premium or discount relative to its financial performance.

In Q4 2023, revenue was flat YoY at $214,761. Net income remained negative at -$5,183,327, with EPS at -0.27. Gross margin was 62.74%, but there was no YoY growth. The financials indicate no significant improvement or growth trends.